PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy

SIMPLE SUMMARY: Over the last decade, immunotherapies using antibodies targeting the programmed cell death 1 (PD-1) checkpoint or its ligand, programmed death ligand 1 (PD-L1), have emerged as promising therapeutic strategies against cancer. However, some current limitations include a relatively low...

Descripción completa

Detalles Bibliográficos
Autores principales: Delmas, Dominique, Hermetet, François, Aires, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467857/
https://www.ncbi.nlm.nih.gov/pubmed/34572736
http://dx.doi.org/10.3390/cancers13184509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467857/
https://www.ncbi.nlm.nih.gov/pubmed/34572736
http://dx.doi.org/10.3390/cancers13184509

Ejemplares similares